Analyst Ratings for Alnylam Pharmaceuticals (ALNY)
ALNY Rating Summary
ALNY Price Target Summary
- Highest: $273.00 (Goldman Sachs)
- Lowest: $98.00 (SVB Leerink)
- Average: $208.40
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$208.40 (+42.3%)
* Over Last 12-Mos
Rating Score: 7.3 / 10
Percentile Rank: 74%
Avg. $ Target:
$208.40 (+42.3%)
* Over Last 12-Mos
Rating Score: 7.3 / 10
Percentile Rank: 74%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/27/2022 | Guggenheim | Debjit Chattopadhyay | Downgrade | Neutral (Buy) |
N/A (N/A) |
147.50 (146.49) |
-0.68% | Details |
| 6/7/2022 | William Blair | Myles Minter | New Coverage | Outperform (N/A) |
N/A (N/A) |
131.63 (146.49) |
11.29% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
ALNY Ratings News
- Guggenheim Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
- KOL Sees 70% of Phase 3 APOLLO-B - Needham & Company Bullish on Alnylam (ALNY) Ahead of patisiran Readout
- Alnylam Pharmaceuticals' (ALNY) Subcutaneous Amvuttra ATTR-PN Approval Is a Key Step for Growth Expansion Plan - Jefferies
- See More
